Belvedere Trading
CERE

Belvedere Trading’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Belvedere Trading’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,001
Closed -$211K – 974
2024
Q1 		$211K Sell
5,001
-1,255
-20% -$52.7K ﹤0.01% 333
2023
Q4 		$265K Buy
+6,256
New +$180K ﹤0.01% 272

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Belvedere Trading's CERE Position: Q2 2024 in Review

Belvedere Trading sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q2 2024, closing a stake of 5,001 shares — an estimated $211K sold.

Belvedere Trading first reported a position in CERE in Q4 2023 and held it in 2 quarters. The position peaked at $265K in Q4 2023. 231 funds tracked by Wall St. Rank hold CERE as of Q2 2024.

  • Belvedere Trading reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Belvedere Trading sold 5,001 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q2 2024, an estimated $211K.
  • Belvedere Trading first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 2 quarters.
  • Belvedere Trading's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $265K in Q4 2023.
  • 231 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q2 2024.

Based on Belvedere Trading's 13F filing for Q2 2024, filed 9 Aug 2024.